Chemomab Therapeutics Ltd
NASDAQ:CMMB
Chemomab Therapeutics Ltd
NASDAQ:CMMB
Price:
1.0699 USD
0.93%
Market Closed
Updated:
Jun 1, 2024
Chemomab Therapeutics Ltd
Cash & Cash Equivalents
|
Chemomab Therapeutics Ltd
Cash & Cash Equivalents Peer Comparison
Comparables:
CLGN
KMDA
URGN
ENTX
B
BONS
Competitive Cash & Cash Equivalents Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Chemomab Therapeutics Ltd
NASDAQ:CMMB
|
Cash & Cash Equivalents
$9.3m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Collplant Biotechnologies Ltd
NASDAQ:CLGN
|
Cash & Cash Equivalents
$26.7m
|
CAGR 3-Years
100%
|
CAGR 5-Years
38%
|
CAGR 10-Years
N/A
|
|
|
Kamada Ltd
NASDAQ:KMDA
|
Cash & Cash Equivalents
$48.2m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
17%
|
CAGR 10-Years
4%
|
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Cash & Cash Equivalents
$131.4m
|
CAGR 3-Years
48%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Cash & Cash Equivalents
$11m
|
CAGR 3-Years
9%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
B
|
Bonus Biogroup Ltd
TASE:BONS
|
Cash & Cash Equivalents
₪26m
|
CAGR 3-Years
17%
|
CAGR 5-Years
25%
|
CAGR 10-Years
42%
|
See Also
What is Chemomab Therapeutics Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
9.3m
USD
9.3m
USD
Based on the financial report for Dec 31, 2023, Chemomab Therapeutics Ltd's Cash & Cash Equivalents amounts to 9.3m USD.
What is Chemomab Therapeutics Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 3Y
-7%
-7%
Over the last year, the Cash & Cash Equivalents growth was -31%. The average annual Cash & Cash Equivalents growth rates for Chemomab Therapeutics Ltd have been -7% over the past three years .
You don't have any saved screeners yet
